Journal of Peking University(Health Sciences) >
Clinical and immunological characteristics of systemic lupus erythematosus with retinopathy
Received date: 2022-08-14
Online published: 2022-12-19
Objective: To investigate the clinical and immunological characteristics of systemic lupus erythematosus (SLE) with retinopathy. Methods: Fifty SLE patients with retinopathy without hypertension and diabetes (retinopathy group) who were hospitalized in the Peking University People's Hospital from January 2009 to July 2022 were screened. Fifty SLE patients without blurred vision during the course of the SLE and without retinopathy in the fundus examinations (non-retinopathy group) matched for sex and age were selected. Their clinical manifestations, laboratory tests and lymphocyte subsets were statistically analyzed. Results: The most common fundus ocular change of the SLE patients with retinopathy was cotton-wool spots (33/50, 66.0%), followed by intraretinal hemorrhage (31/50, 62.0%). Retinopathy could occur at any stage of SLE duration, with a median of 1 year (20 days to 30 years). The proportion of lupus nephritis (72.0% vs. 46.0%, P=0.008) and serositis (58.0% vs. 28.0%, P=0.002) in the retinopathy group were significantly higher than those in the non-retinopathy group. The proportion of neuropsychiatric systemic lupus erythematosus (NPSLE) in the retinopathy group was higher, but there was no significant difference between the two groups. Compared with the non-retinopathy group, the proportion of positive anti-cardiolipin antibody (30.0% vs. 12.0%, P=0.027), the SLEDAI score (median 22.0 vs. 10.5, P < 0.001), erythrocyte sedimentation rate (P < 0.001), C-reactive protein (P=0.019) and twenty-four hours urine total protein level (P=0.026) in the retinopathy group were significantly higher, and the hemoglobin level was significantly lower [(91.64±25.18) g/L vs. (113.96±18.57) g/L, P < 0.001]. The proportion of CD19+ B cells in peripheral blood of the patients with SLE retinopathy was significantly increased (P=0.010), the proportion of CD4+ T cells was significantly decreased (P=0.025) and the proportion of natural killer (NK) cells was lower (P=0.051) when compared with the non-retinopathy group. Conclusion: Retinopathy in SLE suggests a higher activity of SLE disease with more frequent hematologic and retinal involvement. It is recommended to perform fundus examination as soon as a patient is diagnosed with SLE. SLE patients with retinopathy may have stronger abnormal proliferation of B cells, and aggressive treatment should be applied to prevent other important organs involvement.
Min LI , Lin-qing HOU , Yue-bo JIN , Jing HE . Clinical and immunological characteristics of systemic lupus erythematosus with retinopathy[J]. Journal of Peking University(Health Sciences), 2022 , 54(6) : 1106 -1111 . DOI: 10.19723/j.issn.1671-167X.2022.06.008
| 1 | Au A , O'Day J . Review of severe vaso-occlusive retinopathy in systemic lupus erythematosus and the antiphospholipid syndrome: Associations, visual outcomes, complications and treatment[J]. Clin Exp Ophthalmol, 2004, 32 (1): 87- 100. |
| 2 | Moulton VR , Suarez-Fueyo A , Meidan E , et al. Pathogenesis of human systemic lupus erythematosus: A cellular perspective[J]. Trends Mol Med, 2017, 23 (7): 615- 635. |
| 3 | Dammacco R , Procaccio P , Racanelli V , et al. Ocular involvement in systemic lupus erythematosus: The experience of two tertiary referral centers[J]. Ocul Immunol Inflamm, 2018, 26 (8): 1154- 1165. |
| 4 | Yen YC , Weng SF , Chen HA , et al. Risk of retinal vein occlusion in patients with systemic lupus erythematosus: A population-based cohort study[J]. Br J Ophthalmol, 2013, 97 (9): 1192- 1196. |
| 5 | Lanham JG , Barrie T , Kohner EM , et al. SLE retinopathy: Evaluation by fluorescein angiography[J]. Ann Rheum Dis, 1982, 41 (5): 473- 478. |
| 6 | Hochberg MC . Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus[J]. Arthritis Rheum, 1997, 40 (9): 1725. |
| 7 | Gladman DD , Ibanez D , Urowitz MB . Systemic lupus erythematosus disease activity index 2000[J]. J Rheumatol, 2002, 29 (2): 288- 291. |
| 8 | Md Noh UK , Zahidin AZA , Yong TK . Retinal vasculitis in systemic lupus erythematosus: An indication of active disease[J]. Clinics and Practice, 2012, 2 (2): 54. |
| 9 | Stafford-Brady FJ , Urowitz MB , Gladman DD , et al. Lupus retinopathy. Patterns, associations, and prognosis[J]. Arthritis Rheum, 1988, 31 (9): 1105- 1110. |
| 10 | Giorgi D , Pace F , Giorgi A , et al. Retinopathy in systemic lupus erythematosus: Pathogenesis and approach to therapy[J]. Hum Immunol, 1999, 60 (8): 688- 696. |
| 11 | D'Cruz D . Vasculitis in systemic lupus erythematosus[J]. Lupus, 1998, 7 (4): 270- 274. |
| 12 | Kharel R , Shah DN , Singh D . Role of lupus retinopathy in systemic lupus erythematosus[J]. Ophthalmic Inflamm Infect, 2016, 6 (1): 1- 4. |
| 13 | Seth G , Chengappa KG , Misra DP , et al. Lupus retinopathy: A marker of active systemic lupus erythematosus[J]. Rheum Int, 2018, 38 (8): 1495- 1501. |
| 14 | 曹绪胜, 纪海霞, 张永鹏, 等. 全身使用糖皮质激素继发中心性浆液性脉络膜视网膜病变的临床特征[J]. 眼科, 2020, 29 (3): 193- 197. |
| 15 | Million M , Raoult D . The pathogenesis of the antiphospholipid syndrome[J]. N Engl J Med, 2013, 368 (24): 2335. |
| 16 | Jeon S , Lee WK . Aggravated capillary non-perfusion after intravitreal bevacizumab for macular edema secondary to systemic lupus erythematosus and anti-phospholipid syndrome[J]. Lupus, 2012, 21 (3): 335- 337. |
| 17 | Zhu W , Wu Y , Xu M , et al. Correction: Antiphospholipid antibody and risk of retinal vein occlusion: A systematic review and meta-analysis[J]. PLoS One, 2016, 11 (6): e157536. |
| 18 | Lipsky PE . Systemic lupus erythematosus: An autoimmune disease of B cell hyperactivity[J]. Nat Immunol, 2001, 2 (9): 764- 766. |
| 19 | Wei C , Anolik J , Cappione A , et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus[J]. J Immunol, 2007, 178 (10): 6624- 6633. |
| 20 | Hickman RA , Denniston AK , Yee CS , et al. Bilateral retinal vasculitis in a patient with systemic lupus erythematosus and its remission with rituximab therapy[J]. Lupus, 2010, 19 (3): 327- 329. |
| 21 | Damato E , Chilov M , Lee R , et al. Plasma exchange and rituximab in the management of acute occlusive retinal vasculopathy secondary to systemic lupus erythematosus[J]. Ocul Immunol Inflamm, 2011, 19 (5): 379- 381. |
| 22 | Tselios K , Lam WC , Urowitz MB , et al. Rituximab for sight-threatening lupus-related retinal vasculitis[J]. J Clin Rheumatol, 2018, 24 (2): 93- 94. |
| 23 | Liu M , Liu J , Zhang X , et al. Activation status of CD56(dim) natural killer cells is associated with disease activity of patients with systemic lupus erythematosus[J]. Clin Rheumatol, 2021, 40 (3): 1103- 1112. |
/
| 〈 |
|
〉 |